Abatacept and rituximab increase cancer risk in patients with RA

被引：0
|
作者：
机构：
来源：
Reactions Weekly | 2024年 / 2036卷 / 1期
关键词：
D O I：
10.1007/s40278-024-71232-8
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：4 / 4
相关论文
共 50 条
  • [31] Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
    Alping, Peter
    Askling, Johan
    Burman, Joachim
    Fink, Katharina
    Fogdell-Hahn, Anna
    Gunnarsson, Martin
    Hillert, Jan
    Langer-Gould, Annette
    Lycke, Jan
    Nilsson, Petra
    Salzer, Jonatan
    Svenningsson, Anders
    Vrethem, Magnus
    Olsson, Tomas
    Piehl, Fredrik
    Frisell, Thomas
    ANNALS OF NEUROLOGY, 2020, 87 (05) : 688 - 699
  • [32] Change in Rheumatoid Arthritis (RA)-Related Autoantibody Profile and Risk of Disease Flare After Withdrawal of Therapy in Patients with Early RA Treated with Abatacept and MTX
    Toes, Rene
    Lehman, Thomas
    Bryson, Joshua
    Kim, Amy Min
    Balachandar, Sandhya
    Mukherjee, Sumanta
    Maldonado, Michael
    Connolly, Sean
    Huizinga, Thomas
    ARTHRITIS & RHEUMATOLOGY, 2019, 71
  • [33] Common vaccines not shown to increase risk of RA
    Reactions Weekly, 2010, 1311 (1) : 4 - 4
  • [34] EFFECT OF CONCOMITANT STATINS ON RITUXIMAB EFFICACY IN PATIENTS WITH RA
    Vashishtha, A.
    Lehane, P. B.
    Hessey, E. W.
    ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 446 - 446
  • [35] Risk of diverticulitis and gastrointestinal perforation in rheumatoid arthritis treated with tocilizumab compared to rituximab or abatacept
    Rempenault, Claire
    Lukas, Cedric
    Combe, Bernard
    Herrero, Astrid
    Pane, Isabelle
    Schaeverbeke, Thierry
    Wendling, Daniel
    Pham, Thao
    Gottenberg, Jacques-Eric
    Mariette, Xavier
    Morel, Jacques
    RHEUMATOLOGY, 2022, 61 (03) : 953 - 962
  • [36] ABATACEPT IN INDIVIDUALS AT RISK OF DEVELOPING RHEUMATOID ARTHRITIS: RESULTS FROM THE ARTHRITIS PREVENTION IN THE PRECLINICAL PHASE OF RA WITH ABATACEPT (APIPPRA) TRIAL
    Cope, A.
    Jasenecova, M.
    Vasconcelos, J.
    Filer, A.
    Raza, K.
    Qureshi, S.
    D'agostino, M. A.
    Mcinnes, I.
    Isaacs, J.
    Pratt, A.
    Fisher, B.
    Buckley, C. D.
    Emery, P.
    Ho, P.
    Buch, M. H.
    Ciurtin, C.
    Huizinga, T.
    Van Schaardenburg, D.
    Murphy, C.
    Prevost, T.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 86 - 86
  • [37] Comment on: Comparative effectiveness of abatacept, rituximab, tocilizumab and TNFi biologics in RA: results from the nationwide Swedish register: reply
    Frisell, Thomas
    Askling, Johan
    RHEUMATOLOGY, 2019, 58 (08) : 1510 - 1511
  • [38] Shared familial risk factors between cancer and RA patients
    Hemminki, K.
    Li, X.
    Sundquist, K.
    Sundquist, J.
    RHEUMATOLOGY, 2008, 47 (04) : 549 - 551
  • [39] Janus kinase inhibitors in patients with RA: risk of MACE and cancer
    Reactions Weekly, 2022, 1889 (1) : 2 - 2
  • [40] Antibody response to pneumococcal and influenza vaccination in patients with RA receiving subcutaneous abatacept
    Alten, R.
    Bingham, C., III
    Cohen, S.
    Calabrese, L.
    Curtis, J.
    Block, A.
    Fay, J.
    Kelly, S.
    Luo, A.
    Wong, D.
    Genovese, M.
    ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 101 - 102
12345